Skip to content

Effect of Devdaru Choorna in Prameha (Diabetes Mellitus Type 2)

A randomized controlled clinical trial to study the effect of devdaru choorna in prameha with special reference to diabetes mellitus – type 2 - NA

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/08/072285
Enrollment
60
Registered
2024-08-09
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Sponsors

Dr Samiksha Bhure
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient showing signs and symptoms of Prameha such as –1.Prabhuta Mutrata (polyuria) 2. Avila Mutrata(unclear urine)) 3. Ati-sweda (sweating) 4. Daurbalya(weakness) 5. Pipasa(polydipsia) 6. Kshudavriddhi (Polyphagia) 7.Pipilika sancharanvat prachiti 8. Kara dahapada (Burning sensation) 9. Naktamutrata (Nocturnal urination) and patient already diagnosed with DM type 2 such as – b. Age 20-70 years. c. Patient having their Fasting blood glucose level range of 120 - 200 mg/dl. d. Post prandial blood glucose level range of 170 - 250 mg/dl.

Exclusion criteria

Exclusion criteria: 1.IDDM, Acromegaly, Cushing’s syndrome and Pancreatic disorder. 2. Pregnant and lactating women. 3. Patient with gestational diabetes. 4. Patient suffering from Hepatic dysfunction, Renal dysfunction or Liver cirrhosis. 5. Patient in whom DM is caused as drug induced complication. 6. Those who are under Insulin therapy. 7. Patient with DKA, Lactic acidosis, Sepsis. 8. Patients with acute complications like hyperglycaemic coma, ketoacidosis and infections like gangrene. 9. Patients with K/C/O Nephropathy, Neuropathy and Retinopathy. 10. Patients with conditions like cardiovascular disease, acute MI, Immune compromised disease [HIV].

Design outcomes

Primary

MeasureTime frame
Reduction in signs and symptoms of Prameha after ingestion of Devdaru choornaTimepoint: 30 days

Secondary

MeasureTime frame
Where the trial group stands in comparison with control groupTimepoint: 18 months

Countries

India

Contacts

Public ContactDr Samiksha Moreshwar Bhure

SMBT Ayurved College and Hospital

DR.ANKUSH30@gmail.com7359117691

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026